Pharmaceuticals

Denosumab Market Outlook: Growth and Forecast Highlights 2030

February 13, 2026February 13, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the denosumab market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Denosumab Market reach by 2030 starting from 2026 levels?

The denosumab market has experienced rapid expansion in recent years. It is anticipated to grow from $3.67 billion in 2025 to $4.06 billion in 2026, at a compound annual growth rate (CAGR) of 10.7%. The market’s growth during the historic period can be attributed to several factors including the high prevalence of osteoporosis and other bone-related disorders, a burgeoning geriatric population, early approvals for denosumab therapies, increasing capacities of hospitals and specialty clinics, and a rising awareness among patients concerning fracture risk.

The denosumab market is projected to experience swift expansion in the coming years. By 2030, its size is anticipated to reach $6.06 billion, demonstrating a compound annual growth rate (CAGR) of 10.5%. This projected growth during the forecast period is driven by factors such as progress in precision medicine and biologics, the widening availability of homecare and ambulatory services, increased funding for bone health research, the introduction of advanced denosumab formulations, and growing demand within emerging markets. Key trends anticipated for this period involve a greater acceptance of monoclonal antibodies, the expansion of osteoporosis screening initiatives, tailored treatment strategies for bone metastases, an increase in home-based injection therapies, and heightened awareness of bone health among the elderly population.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

Which Drivers Are Influencing Long-Term Growth In The Denosumab Market?

The rising incidence of osteoporosis is anticipated to stimulate the expansion of the denosumab market in the future. This condition involves the weakening of bones, leading to reduced bone density and a greater susceptibility to fractures. Denosumab offers a treatment for osteoporosis by inhibiting bone resorption through its targeted action on the RANK ligand. As an illustration, figures from the Canadian Longitudinal Study on Aging, cited by the US-based National Center for Biotechnology Information in September 2023, indicated that 12.7% of community-dwelling older adult females had physician-diagnosed osteoporosis, while 5.9% had DXA-confirmed osteoporosis. Furthermore, a cross-sectional study by Buttros and colleagues identified a 24.6% prevalence of osteoporosis among postmenopausal women aged 40 to 75, determined via bone mineral density (BMD) measurements. Consequently, the growing occurrence of osteoporosis is a key factor boosting the denosumab market’s expansion.

Which Segments Are Driving Activity In The Denosumab Market?

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Prolia: Prolia 60 Mg Injection, Prolia 1-Year Dosing Schedule, Prolia Osteoporosis Treatment

2) By Xgeva: Xgeva 120 Mg Injection, Xgeva Monthly Dosing Schedule, Xgeva Bone Metastases Management

What Trends Are Projected To Support The Growth Of The Denosumab Market?

Major companies operating in the denosumab market are focusing on expanding global clinical trials and accelerating regulatory approvals to strengthen their competitive position and broaden treatment access. These human-based studies are crucial for assessing the efficacy and safety of new drugs or therapies. As an illustration, during May 2023, Boan Biotech, a Chinese biopharmaceutical company, commenced an international, multi-center Phase 3 clinical trial for its denosumab biosimilars, BA6101 (Boyoubei) and BA1102, with the initial patient enrollment occurring across Europe, the U.S., and Japan. These endeavors build upon its NMPA approval received in 2022 for Boyoubei, designated for postmenopausal women facing a high risk of fractures. Through the advancement of worldwide clinical development and the accumulation of regulatory progress, companies solidify their competitive edge within the denosumab market.

Which Major Industry Participants Are Leading The Denosumab Market Growth?

Major companies operating in the denosumab market are Amgen Inc., Fresenius SE & Co KGaA, Amneal Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd, Biocon Ltd, Sandoz Group AG, Samsung Bioepis Co Ltd, Celltrion Inc, Organon & Co, Shanghai Henlius Biotech Inc, Teva Pharmaceutical Industries Ltd, Accord Healthcare Ltd, CuraTeQ Biologics Pvt Ltd, AryoGen Pharmed Co, BioXpress Therapeutics AG, Henlius Biotech Co Ltd, JHL Biotech Inc, Oncobiologics Inc, Teva International GmbH (Teva biosimilars unit), Hikma Pharmaceuticals PLC, Gedeon Richter Plc, Accord BioPharma Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Denosumab Market?

North America was the largest region in the denosumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Denosumab Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Browse Through More Reports Similar to the Global Denosumab Market 2026, By The Business Research Company

Denosumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Metformin Market Report 2026

https://www.thebusinessresearchcompany.com/report/metformin-global-market-report

Desmoid Tumors Market Report 2026

https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795